Camptosar is a drug owned by Pfizer Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 01, 2020. Details of Camptosar's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6403569 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Apr, 2020
(4 years ago) |
Expired
|
| US6794370 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
May, 2020
(4 years ago) |
Expired
|
|
US6403569 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Oct, 2020
(3 years ago) |
Expired
|
|
US6794370 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Nov, 2020
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Camptosar's patents.
Latest Legal Activities on Camptosar's Patents
Given below is the list of recent legal activities going on the following patents of Camptosar.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 09 Nov, 2016 | US6794370 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Nov, 2016 | US6794370 |
| Correspondence Address Change Critical | 08 Nov, 2016 | US6794370 |
| Correspondence Address Change Critical | 29 Aug, 2014 | US6794370 |
| Recordation of Patent Grant Mailed Critical | 21 Sep, 2004 | US6794370 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Sep, 2004 | US6794370 |
| Issue Notification Mailed Critical | 02 Sep, 2004 | US6794370 |
| Receipt into Pubs | 27 Aug, 2004 | US6794370 |
| Application Is Considered Ready for Issue Critical | 25 Aug, 2004 | US6794370 |
| Dispatch to FDC | 25 Aug, 2004 | US6794370 |
US patents provide insights into the exclusivity only within the United States, but Camptosar is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Camptosar's family patents as well as insights into ongoing legal events on those patents.
Camptosar's Family Patents
Try Our Curated Drug Screens
Generic Launch
Generic Release Date:
Camptosar's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 01, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Camptosar Generics:
Irinotecan Hydrochloride is the generic name for the brand Camptosar. 23 different companies have already filed for the generic of Camptosar, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Camptosar's generic
How can I launch a generic of Camptosar before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Camptosar's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Camptosar's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Camptosar -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg/mL, 2 mL and 5 mL vials | 26 Jul, 2004 | 1 | 20 Feb, 2008 | 01 May, 2020 | Extinguished |
Camptosar Competitors
Understanding your competition is essential for market success. Camptosar which is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan., has several other brand drugs using the same active ingredient (Irinotecan Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Ipsen |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Irinotecan Hydrochloride, Camptosar's active ingredient. Check the complete list of approved generic manufacturers for Camptosar
About Camptosar
Camptosar is a drug owned by Pfizer Inc. It is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan. Camptosar uses Irinotecan Hydrochloride as an active ingredient. Camptosar was launched by Pfizer Inc in 1996.
Approval Date:
Camptosar was approved by FDA for market use on 14 June, 1996.
Active Ingredient:
Camptosar uses Irinotecan Hydrochloride as the active ingredient. Check out other Drugs and Companies using Irinotecan Hydrochloride ingredient
Treatment:
Camptosar is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan.
Dosage:
Camptosar is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG/2ML (20MG/ML) | INJECTABLE | Prescription | INJECTION |
| 100MG/5ML (20MG/ML) | INJECTABLE | Prescription | INJECTION |